The Breast Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing your patients with the best and most individualized treatment options available, including the latest medical oncology, surgical options, breast reconstruction, and radiation therapy.
Our focused and specialized services include programs for: young adults with breast cancer, metastatic breast cancer, inflammatory breast cancer, breast cancer during pregnancy, breast and ovarian cancer genetics and prevention, older adults with breast cancer, patients with breast cancer brain metastases, breast cancer in men, and ductal carcinoma in situ (DCIS).
Featured Content |view more
News
Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark
Breast cancer patients who participated in a remote weight loss intervention program lost an average of 4.7 percent of their baseline body weight after one year, while those in the education only control group gained an average 1 percent ...
News
How Dana-Farber Research Delivered New Medicines and Long-Range Hope for a Patient With Metastatic Breast Cancer
News
Double Negative in Cells Could Undermine PARP Inhibitors
There are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.
Video
DESTINY-Breast09 Presented by Sara Tolaney, MD, MPH.
Dr. Sara Tolaney of Dana-Farber shares pivotal results from the DESTINY-Breast09 phase 3 trial.
Video
TRADE Study Presented by Erica Mayer, MD.
Dr. Erica Mayer shares results from the TRADE study showing a successful abemaciclib dose escalation strategy in patients with HR+ breast cancer.
Document
Our Breast Oncology Center held multidisciplinary meetings to discuss recommendations regarding the use of datopotamab deruxtecan (Dato-DXd) in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
